CClinicalTrials.gg
RecruitingNCT07229352Updated Apr 30, 2026

Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses

An interventional study of Novel spectacle lens design and Spectacle lenses in Myopia, Myopia Progression and Juvenile Myopia, sponsored by SightGlass Vision, Inc.. Recruiting at 1 site in United States. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).

02

Conditions studied

  • Myopia
  • Myopia Progression
  • Juvenile Myopia

Browse trials for

03

In context

Myopia

984 studies on the registry are indexed under Myopia; 210 are open to participants now.

This study's planned enrollment of 20 is below the median of 80 across 783 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

SightGlass Vision, Inc. is the lead sponsor of 14 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

A participant is eligible for inclusion in the study if they meet the following criteria:

  • Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
  • Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
  • Have undergone a self-reported oculo-visual examination within the past two years.
  • Have no active ocular disease.
  • Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
  • Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
  • The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.

Exclusion criteria

Exclusion Criteria:

A participant will be excluded from the study if they meet any of the following conditions:

  • Have any systemic disease that affects ocular health.
  • Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
  • Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
  • Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
  • Have known developmental delays.
  • Have participated in another clinical study in the last 7 days
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    SightGlass Vision Test Arm 1

    Single vision, impact-resistant spectacle lenses

    Device: Novel spectacle lens design

  • Experimental
    SightGlass Vision Test Arm 2

    Single vision, impact-resistant spectacle lenses

    Device: Spectacle lenses

Interventions

  • DeviceNovel spectacle lens design

    Use of lenses may reduce the rate of progression of juvenile myopia

  • DeviceSpectacle lenses

    Use of lenses may reduce the rate of progression of juvenile myopia

06

What researchers measure

Primary outcomes

  1. Reaction time: the time elapsed between the appearance or activation of a visual stimulus and the initiation of the participant's physical response

    Time frame: 2 months

  2. Movement time: the time taken to complete the motor response after it has been initiated.

    Time frame: 2 months

  3. Response accuracy: the correctness of the participant's response to each visual stimulus, measured by the number or percentage of correctly identified or responded-to stimuli.

    Time frame: 2 months

Secondary outcomes

  1. Gait cycle events, such as initial foot contact with the ground and toe-off. It will be used to assess whether the type of eyewear affects natural gait patterns or mobility during peripheral vision tasks.

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
  • Midwestern University Arizona College of Optometry
    Glendale, Arizona 85308, United States
    • Javier Gantes-Nunez · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07229352
Lead sponsor
SightGlass Vision, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Feb 2, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

Jennifer Hill
Contact
jhill@sightglassvision.com
6783614877

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion